- Recent Funding
- Investors
- Philips Health Technology Ventures
Philips Health Technology Ventures portfolio
Philips Health Technology Ventures has 1 portfolio company on record at Recent Funding. Its most recent investment on record is PreciseDx's $11M Series B+ round in June 2025, alongside Quest Diagnostics, Merck Global Health Innovation Fund, LabCorp and 2 others. That company is in Health and bio.
What Philips Health Technology Ventures invests in
- Health and bio · 1 · 100%
- Developer tools and cloud · 1 · 100%
How Philips Health Technology Ventures invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 1 100% | $11M |
Share is of the 1 round on Recent Funding that name Philips Health Technology Ventures. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Philips Health Technology Ventures portfolio companies
PPreciseDx$11MSeries B+ · Jun 2025
| Company | Round with Philips Health Technology Ventures | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $11M | $42.45M | Jun 18, 2025 Series B+ |
Most frequent co-investors
LLabCorp1 shared round · last Jun 18, 2025
QQuest Diagnostics1 shared round · last Jun 18, 2025
GGenHenn Venture1 shared round · last Jun 18, 2025
EEventide1 shared round · last Jun 18, 2025
MMerck Global Health Innovation Fund1 shared round · last Jun 18, 2025
Similar investors
CCategory Ventures1 company · 2 deals in 12 mo
AAmiral Ventures1 company · 1 deal in 12 mo
BBeAble Capital1 company · 1 deal in 12 mo
DDeviation Capital1 company · 1 deal in 12 mo
JJIC Ventures1 company · 1 deal in 12 mo
SShift4Good1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists Philips Health Technology Ventures, which is a subset of its real portfolio. API: /api/v1/investors/philips-health-technology-ventures (get a free API key). More: the most active VC firms and new venture capital funds.